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Herpes simplex virus (HSV) types 1 and 2 are neurotropic viruses that establish lifelong latent infections
in neurons. Mounting evidence suggests that HSV-1 infection is involved in the pathogenesis of Alz-
heimer’s disease (AD). The relationships between other herpesvirus infections and events associated
with neurodegeneration have not, however, been extensively studied. The present work reports that
HSV-2 infection leads to the strong accumulation of hyperphosphorylated tau and the amyloid-b pep-
tides Ab40 and Ab42 (all major pathological hallmarks of AD) in human SK-N-MC neuroblastoma cells.
Infection is also associated with a marked reduction in the amount of Ab40 secreted and in the pro-
teolytic fragments of the amyloid-b precursor protein (APP) (secreted APPa and the a-C-terminal frag-
ment). These results indicate that HSV-2 infection inhibits the nonamyloidogenic pathway of APP
processing and impairs Ab secretion in these cells. In addition, HSV-2 induces the accumulation of
intracellular autophagic compartments containing Ab due to a failure in the late stages of autophagy. To
our knowledge, this is the ﬁrst report to show that HSV-2 infection strongly alters the tau phosphory-
lation state, APP processing, and autophagic process in human neuroblastoma cells, leading to the
appearance of AD-like neurodegeneration markers.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Alzheimer’s disease (AD), the single most common cause of de-
mentia, is characterized by massive neuronal damage leading to
cerebral atrophy and the loss of cognitive function. The major
neuropathological lesions of AD are brain b-amyloidosis and neuro-
ﬁbrillary degeneration; the former is characterized by plaques of
extracellular amyloid-b peptide (Ab) in the brain parenchyma and
blood vessels, while the second involves the intracellular accumu-
lation and aggregation of abnormally hyperphosphorylated tau
protein (a microtubule-associated protein) in the form of neuroﬁ-
brillary tangles (Braak and Braak,1992). Two distinct forms of AD are
recognized: familial and sporadic. Familial AD is caused bymutationslecular “Severo Ochoa”, Uni-
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ll rights reserved.in the genes for amyloid-b precursor protein (APP), presenilin-1, and
presenilin-2. However, most cases of AD (w99%) are of the sporadic
type and usually involve people >65 years (Tanzi, 2012).
Sporadic AD is a highly complex disease for which neither the
causal agent(s) nor the molecular mechanisms behind its patho-
genesis are well known. A growing body of literature suggests,
however, that cerebral infections may be risk factors for neurode-
generative disease, and certainly numerous studies have revealed
an association between herpes simplex virus type 1 (HSV-1) and AD
(Itzhaki, 2014; Piacentini et al., 2014). For example, HSV-1 DNA is
present in the brains of a high proportion of people with AD
(Jamieson et al., 1991), mainly within amyloid plaques (Wozniak
et al., 2009b), the virus has been shown capable of inducing the
main hallmarks of AD pathology (Alvarez et al., 2012; Santana et al.,
2012b; Wozniak et al., 2007, 2009a), and the analysis of data
gathered in genome-wide association studies involving thousands
of AD patients and controls identiﬁed a set of AD-linked gene var-
iants that might increase brain susceptibility to viral infections,
particularly HSV-1 infection (Porcellini et al., 2010). Few studies,
however, have focused on the role of other herpesviruses in AD,
even though 5dherpes simplex virus type 2 (HSV-2), cytomega-
lovirus (CMV), human herpes virus 6, varicella-zoster virus and
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elderly individuals and AD patients (Carbone et al., 2014; Hemling
et al., 2003; Lin et al., 2002).
Like HSV-1 (which causes cold sores), HSV-2 (which causes
genital herpes) belongs to the alpha-herpesvirus subfamily. These
viruses can reach the sensory neurons that innervate the site of
primary infection, and establish lifelong latent infections. Reac-
tivation from the latent state causes recurrent disease, which is
particularly common in immunocompromised hosts (Steiner and
Benninger, 2013). A recent study estimates 57% of US adults to be
infected with HSV-1 and 17% with HSV-2 (Koelle and Corey, 2008).
It is well known that HSV-2 can infect the brain and cause neuro-
logical problems such as encephalitis and meningitis in neonates
and encephalitis in adults (Berger and Houff, 2008). HSV-2 DNA,
however, is found in the brains of far fewer people than HSV-1 DNA
(both in those with AD and age-matched controls) (Lin et al., 2002).
There are few comparative studies of HSV-1 and HSV-2 central
nervous system infections, but it has traditionally been thought that
HSV-2 causes fewer cases of herpes simplex encephalitis in adults
than HSV-1 (w10% compared to w90%) (Berger and Houff, 2008).
However, a recent report suggests that HSV-1 and HSV-2 account
for similar numbers (Moon et al., 2014). These discordant ﬁndings
may result from ethnic or regional differences between the study
populations. In addition, the latter study has some limitationsdall
patients belong to a single center and it is a retrospective studywith
not well-deﬁned criteria for categorization of neurological diseases.
Further studies with well-designed prospective studies in multiple
centers and regions are required to conﬁrm that HSV-2 is a major
cause of severe encephalitis in adults.
Our group and others have reported HSV-1 infection to modify
tau phosphorylation (Alvarez et al., 2012; Wozniak et al., 2009a;
Zambrano et al., 2008), APP proteolytic processing (De Chiara
et al., 2010; Santana et al., 2012b; Wozniak et al., 2007), and auto-
phagy (Gobeil and Leib, 2012; Santana et al., 2012a), all of which
have been associated with the pathogenesis of AD. However, the
effect of HSV-2 infection on these processes has not been exten-
sively studied. The present work reveals that, like HSV-1 infection,
HSV-2 infection can provoke the appearance of the neuro-
degeneration markers characteristic of AD in different cell models.
2. Materials and methods
2.1. Drugs, plasmids, and antibodies
Heparin (10 mg/mL), rapamycin (0.2 mg/mL), and baﬁlomycin A1
(100 nM) were purchased from Sigma. Leupeptin (100 mM) was
supplied by Roche. 40, 6-diamidino-2-phenylindole (DAPI; 5 mg/mL)
andammoniumchloride (NH4Cl; 20mM)were obtained fromMerck.
The GFPelight chain 3 (LC3) expression vector (pGFP-LC3) and
the mCherry-GFP-LC3 construct (dtLC3) were kind gifts from T.
Yoshimori and N. Mizushima (Kabeya et al., 2000), and T. Johansen
(Pankiv et al., 2007), respectively. Rabbit anti-HSV glycoprotein B
and D (gB/gD) antibody was kindly provided by E. Tabares. Mouse
anti-APP A4 antibody (clone 22C11) was purchased from Millipore
(MAB348). Monoclonal anti-human b-amyloid protein [1e17]
(clone 6E10) was supplied by Sigma (A1474). Rabbit anti-amyloid
precursor protein, C-terminal, antibody, recognizing all APP
carboxy-terminal fragments (CTFs), was purchased from Sigma
(A8717). Rabbit polyclonal anti-Ab40 (44348A) and anti-Ab42
(44e344) unconjugated antibodies, (pS199), (pT205), (pT231),
(pS404), and (pS422) tau polyclonal antibodies (44734G; 44738G;
44746G; 44758G, and 44764G) and tau (TAU-5) monoclonal anti-
body (AHB0042) were purchased from Life Technologies. Two anti-
LC3 antibodies were used: rabbit anti-LC3B from Sigma (L7543) and
rabbit polyclonal anti-LC3 from MBL (PD014). Human CD63antibodywas obtained from the Developmental Studies Hybridoma
Bank, University of Iowa (CD63, clone H5C6). Rabbit serum anti-GFP
came from Life Technologies (A-6455). Mouse monoclonal anti-
tubulin antibody was supplied by Sigma (T5168). The secondary
antibodies used for immunostaining were horseradish peroxidase-
coupled antibodies (Vector), or antibodies labeled with Alexa Fluor
488 or 555 dyes (Invitrogen).
2.2. Cell culture
Vero and SK-N-MC (human neuroblastoma) cell lines used in this
work were purchased from the American Type Culture Collection.
SK-N-MC cells stably expressing human APP (SK-APP) (Recuero
et al., 2004) or GFP-LC3 (SK-LC3) (Santana et al., 2012b) were pro-
duced in-house. The SK-N-MC cells were grown as monolayers in
minimal Eagle’s medium supplemented with 10% heat-inactivated
fetal calf serum, 2 mM glutamine and 50 mg/mL gentamicin. Vero
cells were passaged in Dulbecco’s modiﬁed Eagle medium supple-
mented with 10% fetal calf serum, 2-mM glutamine, and 50-mg/mL
gentamicin. All cells were grown at 37 C in a 5% CO2 atmosphere.
2.3. HSV-2, infection, plaque assays, and viral DNA quantiﬁcation
HSV-2 strain 333 was propagated on a monolayer of Vero cells as
previously described (Carrascosa et al., 1982) and stored at 70 C.
The infectious titers of HSV-2 were determined by plaque assay
(Santana et al., 2012b). For infection experiments, cells were grown
in 6-well plates (for Western blot assays) or 24-well plates with
coverslips (for immunoﬂuorescence assays). When the cells reached
70%e80% conﬂuence they were exposed to HSV-2 at 37 C for 1 hour.
Mock infections were performed using a virus-free suspension. Un-
bound virus was removed and the cells incubated in complete
medium. Times and multiplicities of infection (expressed as plaque-
forming units per cell [pfu/cell]) are as indicated in each experiment.
Viral DNA levels were quantiﬁed by real-time quantitative poly-
merase chain reaction in the presence of SYBR Green, using primers
speciﬁc for the overlapping region of UL18 and UL19 genes of HSV-2
(50-GCTCCCCCCCGTGGA-30 and 50-AGGATTTCGCGCAGGTGAT-30),
employing an ABI Prism 7900HT SD system (Applied Biosystems).
The quantiﬁcation of human genomic DNA was performed using an
Assay-on-Demand probe speciﬁc for the glyceraldehyde-3-phos-
phate dehydrogenase housekeeping gene (Applied Biosystems; item
nu Hs99999905_m1). The quantiﬁcation results were calculated as
viral DNA copy numbers per ng of genomic DNA.
2.4. Immunoﬂuorescence analysis
Cells grown on coverslips were ﬁxed in 4% formaldehyde and
incubated with the appropriate primary and secondary antibodies.
DAPI was added 10 minutes before the end of the procedure to
visualize the nuclei. GFP-LC3 and dtLC3 imaging was performed in
the same way but without antibody incubations. All cells were
examined using a Zeiss Axiovert 200 ﬂuorescence microscope or a
Zeiss LSM710 vertical confocal microscope equippedwith a 63 oil-
immersion objective. Pictures were taken with a Spot RT slider
digital camera (Diagnostic) using Metamorph 5.07 (Universal Im-
aging Corporation) or ZEN 2012 (Carl Zeiss Microscopy GmbH) im-
aging system software, and processed using Adobe Photoshop CS4.
2.5. Western blot analysis
For Western blot assays, cells were treated with lysis buffer
(50-mM Tris-HCl pH 7.6, 300-mM NaCl, and 0.5% Triton X-100) con-
taining a protease inhibitor cocktail (Complete Mini, Roche) and
incubated for 30 minutes at 4 C. For tau analysis, cells were lysed in
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mM NaCl, 0.2% sodium deoxycholate, 1% Nonidet P-40%, and 0.1%
sodium dodecyl sulfate) containing protease and phosphatase in-
hibitor cocktails (PhosSTOP, Roche), and incubated for 30 minutes at
4 C. Lysates were centrifuged at 13,000g for 15 minutes at 4 C. For
endogenous LC3 analysis, lysates were prepared as described else-
where (Santana et al., 2012b). Determinations of protein content
were performed using the bicinchoninic acid assay (Pierce). For
secreted APP analysis, the conditioned medium was treated with a
protease inhibitor cocktail and concentrated 10 fold. Cell lysates and
mediumwere mixed with Laemmli buffer, sonicated, and heated for
5 minutes at 100 C. After electrophoretic separation, the gels were
blotted onto a nitrocellulose membrane and stained with the
appropriate antibodies. A peroxidase-coupled antibodywasused as a
secondary antibody. Detection byenhanced chemiluminescencewas
performed using ECL Western blotting detection reagents (Amer-
sham Biosciences) according to the manufacturer’s instructions.
2.6. Measurement of secreted Ab
SK-APP cells were infected with HSV-2 and the medium later
assayed for human Ab40 using a commercial sandwich enzyme-
linked immmunosorbent assay kit (Life Technologies) as
described elsewhere (Santana et al., 2012b).
2.7. Secretase activity assays
a- and b-secretase activity was determined using commercial
kits (R&D Systems) according to the manufacturer’s instructions, as
described elsewhere (Santana et al., 2012b).
2.8. Statistical analysis
Graph values are expressed as mean  standard error of the
mean. Differences between groups were analyzed using the 2-
tailed Student t test. Signiﬁcance was recorded at p < 0.05 (*), p <
0.01(**), and p < 0.001(***). Before analysis, the largest and the
smallest variances were tested for homogeneity using the F-test.
3. Results
3.1. HSV-2 induces the accumulation of hyperphosphorylated tau
Before all else, the HSV-2 infection parameters for the SK-N-MC
cells were optimized. In this cell model, HSV-2 establishes a lyticFig. 1. HSV-2 infection leads to increased tau phosphorylation. SK-N-MC cells were expose
phosphorylation-sensitive antibodies ser199, thr205, thr231, ser404, and ser422. An antibo
mock and HSV-2-infected cells. DAPI-stained nuclei are shown. Scale bar: 10 mm. (B) Wester
equal loading. The blots are representative of 3 independent experiments. (C) Phosphorylate
of phospho-tau to total tau in HSV-2-infected cells with respect to noninfected cells is repre
(*p < 0.05; **p < 0.01; ***p < 0.001). Abbreviations: DAPI, 40 , 6-diamidino-2-phenylindole;replication cycle resulting in cell lysis w20e22 hours after infec-
tion. In this work, all infections were performed at a moi of 10 pfu/
cell because this viral dose guarantees that almost all cells become
infected, as revealed by confocal images of HSV-2-infected cells,
visualized via the use of an antibody that recognizes glycoproteins B
and D of the virus (Supplementary Fig. 1).
Immunoﬂuorescence analysis was used to determine whether
HSV-2 infection modiﬁes the phosphorylation state of tau in SK-N-
MC cells. For this, the Tau-5 antibody, which reacts with a
phosphorylation-independent epitope, and the phosphorylation-
sensitive antibodies ser199, thr205, thr231, ser404, and ser422
were used. In noninfected cells, phosphorylation-sensitive anti-
bodies stained the cytoplasm only weakly (Fig. 1A). It should be
noted that, except for the ser404 epitope, stronger immunoreac-
tivity was observed in mitotic cells (Supplementary Fig. 2); this is
consistent with the results of other authors (Delobel et al., 2002)
who reported that the abnormal tau-phosphorylation characteristic
of AD also occurs during mitosis. When the cells were exposed to
HSV-2, all the tested epitopes revealed an accumulation of phos-
phorylated tau (Fig. 1A). Western blot analysis was used to quantify
the effects of HSV-2 infection on tau phosphorylation (Fig. 1B). As
suggested by the immunoﬂuorescence experiments, a signiﬁcant
increase of phosphorylated tau levels was observed in all the
examined epitopes compared to noninfected cells (Fig. 1C). How-
ever, the infected cells actually showed a small reduction in total
tau levels, ruling out the possibility that the increase in phosphor-
ylated tau induced by HSV-2 was due to an increase in tau content.
HSV-1 infection has previously been shown to induce the
intranuclear accumulation of hyperphosphorylated tau at viral
replication sites (Alvarez et al., 2012). In the presentwork, when the
staining patterns of the phosphorylation-sensitive antibodies and
the nuclear counterstain DAPI in HSV-2-infected cells were exam-
ined by confocal microscopy, the structures stained by the ser199,
thr231, and ser404 antibodies were seen to ﬁll the large, dark holes
that appear in the nuclei of infected cells (Supplementary Fig. 3).
Numerous reports have revealed that dark areas of DAPI staining
coincide with the location of the viral replication centers (Calle
et al., 2008; Wilcock and Lane, 1991). These data therefore indi-
cate that some of the hyperphosphorylated tau accumulates within
the nuclei of HSV-2-infected cells.
3.2. HSV-2 modiﬁes the levels of Ab and APP proteolytic fragments
Tests were next performed to determine whether HSV-2 also
modulates APP processing. It has previously been shown that HSV-1d to HSV-2 at 10 pfu/cell for 18 hours and tau phosphorylation was assessed using the
dy that recognizes total tau (Tau5) was also used. (A) Immunoﬂuorescence images of
n blot analysis of endogenous tau levels. A tubulin blot is shown as a control to ensure
d tau levels normalized by total tau were quantiﬁed by densitometric analysis. The ratio
sented. Data are the mean  standard error of the mean of 3 independent experiments
HSV-2, herpes simplex virus type 2.
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its secretion (Santana et al., 2012b). As a ﬁrst step, the Ab levels in
the SK-N-MC cell line overexpressing the human APP protein (SK-
APP) were examined by immunoﬂuorescence. Intracellular Ab was
undetectable in noninfected cells at both test times (Fig. 2A). In
contrast, HSV-2 infection induced a strong elevation of both the
main intracellular species of Ab peptide at 18 hours postinfection
(hpi). In fact, this increase began at least at 6 hpi (Fig. 2B), indicating
that HSV-2 induces Ab accumulation early in infection. Similar re-
sults were obtained in Vero cells (Supplementary Fig. 4), another
cell type inwhich HSV-1 has been reported to increase intracellular
Ab levels (Wozniak et al., 2011). The Ab40 content of the extracel-
lular medium of infected and noninfected SK-APP cells was then
determined by enzyme-linked immmunosorbent assay. When
these cells were infected with HSV-2, the Ab40 levels fell drastically
(by >4 fold). Neither Ab42 nor intracellular Ab was detectable by
this assay. To conﬁrm that the reduction in Ab40 was provoked by
HSV-2 infection, the cells were treated with heparin, an inhibitor of
herpesvirus entry; this completely stopped the reduction in Ab40
previously recorded (Fig. 2C). Heparin treatment drastically reduced
the levels of HSV-2 DNA demonstrating that heparin efﬁciently
blocked viral replication in SK-APP cells (>99%; Fig. 2D), thus
ensuring that the effect of heparin on Ab secretionwas mediated by
inhibition of HSV-2 infection.
To investigate how HSV-2 infection impacts APP processing, the
activities of a- and b-secretases were recorded using speciﬁc ﬂuo-
rescent activity assays. Analysis of HSV-2-infected cells revealedFig. 2. Effects of HSV-2 infection on Ab levels. SK-APP cells were mock-infected (A) or infe
activities analyzed by immunoﬂuorescence. Images of DAPI-stained nuclei are shown. Sc
extracellular Ab40 levels in conditioned medium from mock and HSV-2-infected SK-APP cu
heparin on viral DNA levels was analyzed by real-time quantitative polymerase chain rea
representative experiment of 3 performed. Abbreviations: Ab, amyloid beta; DAPI, 40 , 6-diatheir a-secretase activity to be reduced by 40% compared to
noninfected cells. In contrast, no changes were recorded in b-sec-
retase activity after HSV-2 infection (Fig. 3A). Consistent with these
data, when the generation of products resulting from a-secretase
activity was examined byWestern blotting, HSV-2 infection led to a
dramatic reduction in secreted sAPPa (Fig. 3B) and a-CTF (Fig. 3C).
No signiﬁcant differences were detected in APP expression in the
cells after infection with HSV-2 (Fig. 3D), ruling out that the alter-
ation of the different APP proteolytic products was due to any
change in the actual amount of APP available.
Taken together, these ﬁndings are consistent with those ob-
tained in HSV-1-infected cells and suggest that infection with
herpesviruses strongly modiﬁes APP processing and Ab levels.
3.3. Inhibition of autophagic ﬂux in HSV-2-infected cells
HSV-1 has been reported to strongly alter autophagy, a major
degradative pathway of the lysosomal system known to be much
impaired in AD. The microtubule-associated protein 1 LC3 is syn-
thesized as a precursor (proLC3) which is proteolytically processed
into the cytosolic LC3-I isoform. On activation of autophagy, LC3-I is
modiﬁed into the phosphatidylethanolamine-conjugated form, LC3-
II, which speciﬁcally binds to autophagicmembranes. Changes in LC3
provide a very useful marker of autophagy and can be monitored by
immunoﬂuorescence andWestern blotting (Klionsky et al., 2012). To
examine theeffects ofHSV-2 infectiononautophagy, theendogenous
LC3 levels of SK-N-MC cells were determined. Immunoﬂuorescencected with HSV-2 at 10 pfu/cell for 6 and 18 hours (B), and Ab40 and Ab42 immunore-
ale bar: 10 mm. (C) Quantitative analysis by enzyme-linked immunosorbent assay of
ltures (10 pfu/cell) after 18 hpi in the presence or absence of heparin. (D) The effect of
ction. In (C) and (D), data are the mean  standard deviation for 3 samples from a
midino-2-phenylindole; hpi, hours post infection; HSV-2, herpes simplex virus type 2.
Fig. 3. HSV-2 infection inhibits the nonamyloidogenic pathway of APP processing. SK-APP cells were mock-infected or exposed to HSV-2 at 10 pfu/cell for 18 hours in all panels. (A)
Analysis of a- and b-secretase activities by ﬂuorogenic assays. The relative secretase activities were calculated and normalized by the amount of protein in the lysates in comparison
with that seen for mock-infected cells. Data are the mean  standard deviation for 3 samples from a representative experiment of 3 performed. (B) Secreted APP (sAPP) levels in
conditioned medium in which SK-APP cells were cultured were analyzed by Western blotting using 2 different anti-APP antibodies: 22c11 (upper panel) and 6E10 (speciﬁcally
recognizes sAPPa; lower panel). (C) Analysis of a-CTF levels by Western blotting using an antibody that recognizes all CTFs of APP (A8717). The b-CTF fragment was undetectable in
these conditions. (D) APP levels in lysates were examined byWestern blotting using the 22c11 antibody. Tubulin blots were performed as a loading control. The ratio of the analyzed
proteins in HSV-2-infected cells with respect to mock-infected cells is shown at the bottom of the blots. Abbreviations: APP, amyloid-b precursor protein; CTF, carboxy-terminal
fragment; HSV-2, herpes simplex virus type 2.
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reactivity, suggesting an accumulation of autophagic compartments
in infected cells (Fig. 4A). To better quantify the effects of infection,
the lipidation of LC3 was monitored byWestern blotting. Consistent
with the results obtained for the immunoﬂuorescence experiments,
endogenousLC3-II levelsweremarkedly increased in cells exposed to
HSV-2 at 18 hpi (Fig. 4B). In addition, the distribution of LC3 in SK-N-
MC cells stably expressing the GFP-LC3 fusion protein (SK-LC3) was
studied by ﬂuorescence microscopy. In noninfected cells, few GFP-
LC3 spots were observed. In contrast, GFP-LC3-positive structuresFig. 4. HSV-2 infection induces the accumulation of autophagosomes in SK-N-MC cells. In a
infected with HSV-2 for 18 hours were analyzed by immunoﬂuorescence using an anti-LC3
HSV-2-infected cells after 18 (B) or 8 hours (C) in the absence or presence of the lysosomal i
protein was used. Tubulin blots are shown as a control of equal loading. The ratio of LC3-
independent experiments. Abbreviations: LC3, light chain 3; HSV-2, herpes simplex virus taccumulated in HSV-2-infected cells (Supplementary Fig. 5A).When
the GFP-LC3 levels were analyzed by Western blotting, HSV-2 was
seen to provoke a strong accumulation of the autophagy-associated
isoform GFP-LC3-II (Supplementary Fig. 5B). These results were
reproduced inVero cells (which are also susceptible toHSV infection)
(Supplementary Fig. 6A and B).
Increased LC3-II levels could stem from the overactivation of
autophagy or reduced autophagic turnover due to defects in the late
stages of autophagic degradation. Determining LC3-II levels in the
presence of the lysosomal inhibitors leupeptin (a lysosomal proteasell panels, cells were infected with HSV-2 at 10 pfu/cell. (A) Mock-infected cells or cells
antibody. Scale bar: 10 mm. (B and C) Western blot analysis of endogenous LC3 levels in
nhibitors leupeptin (leu) and ammonium chloride (NH4Cl). An antibody speciﬁc for LC3
II to tubulin is shown at the bottom of the blots. All the blots are representative of 4
ype 2.
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neutralizes the acidic lysosomal pH) by Western blotting is a well-
established means of measuring autophagic ﬂux. With the lyso-
somal inhibitor treatment, endogenous LC3-II levels dramatically
increased in noninfected SK-N-MC cells (>10 fold) indicating a
functional lysosomal degradation of LC3-II. However, when cells
were exposed to HSV-2, a modest increase in LC3-II was recorded in
thepresenceof lysosomal inhibitors (1.5 fold)during the late stagesof
infection (18 hpi), suggesting autophagosome turnover becomes
blocked in HSV-2-infected cells (Fig. 4B). When the effect of lyso-
somal inhibitors was analyzed in SK-LC3 cells, similar results were
obtained (Supplementary Fig. 5B). These ﬁndings, which were also
reproduced in Vero cells (Supplementary Fig. 6B), indicate that only
some of the LC3-II molecules are degraded by lysosomes in HSV-2-
infected cells, resulting in the accumulation of autophagosomes. In
contrast,when these experimentswereperformed in theearly stages
of infection (8 hpi) in SK-N-MC (Fig. 4C) and Vero (Supplementary
Fig. 6C) cells, treatment with lysosomal inhibitors caused a similar
increase in endogenous LC3-II levels in both noninfected andHSV-2-
infected cells, indicating that HSV-2-infected cells experience unal-
tered autophagic ﬂux early in infection.
The tandem ﬂuorescent-tagged LC3 constructdthe mCherry-
GFP-LC3 reporter (dtLC3)dwas used to conﬁrm the inhibition of
autophagic ﬂux in HSV-2-infected cells. The acidic lysosomal
environment quenches GFP ﬂuorescence but not mCherry ﬂuores-
cence. Therefore, when autophagosomes fuse with lysosomes, GFP
ﬂuorescence from dtLC3 is lost and only red ﬂuorescence is recor-
ded. In noninfected SK-N-MC cells, and cells treatedwith rapamycinFig. 5. Impairment of autophagic ﬂux in HSV-2-infected cells. SK-N-MC cells were transientl
treated with baﬁlomycin A1 (Baf A1) or rapamycin. Confocal microscopy images were taken
green and red signals under the different conditions assayed. Scale bar: 10 mm. Abbreviatioto induce autophagy, yellow and red vesicles appeared, revealing
the formation of autophagosomes and autolysosomes and thus
demonstrating functional autophagy. A signiﬁcant increase in the
number of vesicles was seen in rapamycin-treated cells, consistent
with the activation of autophagy induced by the drug. In contrast, a
marked increase in the number and proportion of yellow puncta
was observed in cells infected with HSV-2 at 18 hpi compared with
nontreated cells. These effects are analogous to the changes pro-
duced by lysosomal alkalinization induced by baﬁlomycin A1
(Fig. 5) and are indicative of accumulation of autophagosomes,
probably caused by a failure in the autophagosome-lysosome fusion
process.
Taken together, these results indicate that HSV-2 blocks auto-
phagic ﬂux in the late stages of the viral replication cycle.
3.4. HSV-2 induces the accumulation of Ab in autophagosomes
To further investigate the relationship between autophagosome
accumulation and alterations in APP processing, the intracellular
distribution of Ab was monitored in HSV-2-infected cells by
confocal microscopy. To this end, SK-APP cells were stained for Ab,
along with markers for autophagic compartments (LC3), and late
endosomes and/or lysosomes (CD63). Ab and LC3 immunoreactiv-
ities were almost undetectable in noninfected cells, whereas CD63
showed a characteristic punctate cytosolic pattern (Fig. 6A). Anal-
ysis of the confocal images revealed Ab structures to colocalize with
endogenous LC3 in cells exposed to HSV-2, indicating that Ab was
located in autophagic compartments (Fig. 6B). The colocalization ofy transfected with mCherry-GFP-LC3 reporter and infected with HSV-2 at 10 pfu/cell, or
after 18 hours of treatment. The insets in the merged panels show the colocalization of
n: HSV-2, herpes simplex virus type 2.
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somes are the destiny organelles of the autophagic pathway where
the vesicular contents are degraded. When SK-APP cells were
infected with HSV-2, no colocalization of CD63 with either Ab
isoform was detected (Fig. 6C).
Taken together, these results show that Ab does not reach the
lysosomal compartment resulting in the accumulation of Ab in
autophagosomes, conﬁrming a failure in autophagic ﬂux in HSV-2-
infected cells.
4. Discussion
AD is a multifactorial disorder that apparently involves different
etiopathogenic mechanisms. One of the factors involved may be
infectious agents that are able to colonize the brain and thus escapeFig. 6. Intracellular Ab colocalizes with endogenous LC3 in herpes simplex virus type 2 (HS
then examined by confocal microscopy. (A) Mock-infected cells were immunostained for Ab
Confocal images of HSV-2-infected cells obtained with anti-Ab and anti-LC3 antibodies. T
Confocal images of cells exposed to HSV-2 showing the staining pattern of Ab40, Ab42, and
green and red signals. Scale bar: 10 mm. Abbreviations: Ab, amyloid beta; LC3, light chain 3the immune response. Infection by different members of the
herpesvirus family may be a risk factor for AD. These viruses are
highly prevalent in the human population and the infection rate
increases with age, they can infect neurons, and they establish life-
long latent infections that cannot be removed by the immune sys-
tem. Most of the studies have focused on the relationship between
HSV-1 and AD but with nearly 70% genetic homology and a very
similar transcription map, HSV-2 is a closely related virus (Aguilar
et al., 2006), and it would not be surprising to discover that HSV-2
infection has effects similar to HSV-1 infection on processes whose
modiﬁcation has been related to neurodegeneration. Certainly it is
well known that HSV-2 can infect the brain and that it is associated
with neurological alterations (Steiner and Benninger, 2013), but its
impact on the appearance of AD-like neurodegeneration markers
has not been studied in depth. In this report, HSV-2 infection isV-2)-infected cells. SK-APP cells were exposed to HSV-2 at 10 pfu/cell for 18 hours and
, LC3, and CD63 proteins. Ab and LC3 signals are undetectable in these conditions. (B)
he insets in the merged panels show the colocalization of green and red signals. (C)
CD63 proteins. The insets in the merged panels show the absence of colocalization of
.
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supporting the hypothesis of an active role for this and perhaps other
herpesviruses in AD.
Neuroﬁbrillary degeneration is a major neuropathological hall-
mark of AD. It results from the aggregation of abnormally phos-
phorylated tau protein as paired helical ﬁlaments (PHFs). Tau is
found in the adult brain in 6 isoforms, generated by alternative
splicing, ranging from 48 to 68 kDa in molecular weight (Goedert
and Jakes, 1990). In the present work, a complex band pattern
characteristic of the expression of all 6 tau isoformswas obtained in
SK-N-MC cells. In cell cultures exposed to HSV-2, all 5 examined
epitopes reported an increase in phosphorylated tau levels, and the
band proﬁle of phospho-tau species became very complex. The
present ﬁndings are similar to those reported in AD and other
tauopathies, in which a band proﬁle of phospho-tau strongly
dependent on the phospho-speciﬁc tau antibody used is reported
(Puig et al., 2005; Santpere et al., 2006). Importantly, all the sites
examined in the present work are reported to be hyper-
phosphorylated in PHF tau in AD brains (Lovestone and Reynolds,
1997), which supports the role of herpesviruses in promoting
aberrant tau phosphorylation in AD. In addition, confocal analysis
showed that some of the phosphorylated tau species induced by
HSV-2 accumulate in the nucleus. Consistent with these results,
previous work performed at our laboratory has shown hyper-
phosphorylated tau to accumulate in the viral replication com-
partments in the nucleus of HSV-1-infected cells (Alvarez et al.,
2012). The effect of nuclear accumulation of phosphorylated tau
induced by HSV might not be related to tangle formation. However,
tau phosphorylation may determine the recruitment of tau to the
nucleus, or may alter tau activity to promote the viral replication
and/or transcription processes in neuronal cells, with the conse-
quence of neurodegeneration. Alternatively, cellular proteins may
be targeted to damaged viral DNA that arises during replication
(Mohni et al., 2010). In this respect, a role of tau in neuronal DNA
protection has been recently described (Sultan et al., 2011). Further
studies are required to examine the role of nuclear phosphorylated
tau in herpesvirus infections. In addition, HSV-2 also increases tau
phosphorylation in the cytoplasm of infected cells. The accumula-
tion of hyperphosphorylated tau in the cell body could contribute to
the generation of PHFs and, therefore, to the neurodegeneration
characteristic of AD. The functional signiﬁcance of these differential
phosphorylation events is unclear but suggests that tau protein is a
relevant target of HSV-2 infection and may play a functional role in
the infection process.
It is well established that the buildup of intracellular Ab is one of
the earliest events in the pathogenesis of AD (LaFerla et al., 2007).
HSV-2 infection was found to increase intracellular Ab levels and to
intensely inhibit Ab secretion. Ab accumulation has also been
shown to be induced by other brain pathogens related to AD, sup-
porting the infectious hypothesis (Miklossy, 2011). Recent work has
shown that Ab may act as a defensive molecule of the innate im-
mune system, with activity against several bacteria and yeasts
(Soscia et al., 2010), inﬂuenza A virus (White et al., 2014), and HSV-1
(Bourgade et al., 2014). This role is consistent with the idea that
viral infections are associated with the etiology and pathogenesis of
AD. Herpesviruses and other infectious agents might trigger an
overproduction of Ab peptides, which might contribute to amyloid
plaque formation and the progression of AD.
b-secretase is the initiating and rate-limiting enzyme in the
production of Ab (Cai et al., 2001). There are numerous reports that
an increase in the activity of b-secretase leads to the accumulation
of intracellular Ab, contributing to AD pathogenesis. In the present
work, no signiﬁcant changes were seen in b-secretase activity in
HSV-2-infected cells. However, HSV-2 induced a potent inhibition of
a-secretase activity alongwith a strong reduction in the levels of theproteolytic products a-CTF and sAPPa. This indicates a down-
regulation of the nonamyloidogenic pathway of APP processing in
infected cells. Finally, the accumulation of intracellular Ab in LC3-
positive compartments strongly suggests a failure in Ab degrada-
tion in the autophagic compartments induced by HSV-2. To test this
hypothesis, the effects of HSV-2 on autophagy were analyzed and it
was found that HSV-2 induced amarked increase in the levels of the
autophagosome-associated LC3-II isoform, resulting in the accu-
mulation of autophagic compartments in infected cells. Autophagy
defects might play a role in neurodegenerative disorders, especially
in AD. Indeed, large accumulations of autophagic compartments in
AD brains have been reported (Nixon et al., 2005), indicating
impaired clearance of autophagosomes rather than any strong in-
duction of autophagy (Nixon and Yang, 2011). In line with these
ﬁndings, the strong accumulation of autophagosomes induced by
HSV-2 seems to be due to a failure in the autophagic ﬂux. This in
turn seems to be provoked by a defect in autophagosome-lysosome
fusion. Interference with the late stages of autophagy might there-
fore enhance the accumulation of Ab in autophagosomes in infected
cells. Our group has previously reported that HSV-1 induces similar
alterations in APP processing and autophagy pathways (Santana
et al., 2012a, 2012b). Taken together, the present ﬁndings suggest
that the intracellular accumulation of Ab caused by HSV-2 infection
is produced by the inhibition of Ab secretion and the failure of Ab
degradation by lysosomes. The inhibition of the nonamyloidogenic
pathway might also contribute to this accumulation.
Numerous experimental ﬁndings suggest the implication of
HSV-1 infection in AD pathogenesis [see recent reviews by Itzhaki,
2014; Piacentini et al., 2014] and there is growing evidence that
other herpesviruses might be involved. The presence of IgM anti-
HSV antibodies (recognizing HSV-1 and HSV-2 antigens) in
serumda marker of HSV reactivationdwas found to be correlated
with an increased risk of developing AD (Letenneur et al., 2008;
Lovheim et al., 2014). Recently, EBV and human herpes virus 6
DNA positivity, along with CMV and EBV IgG plasma levels, were
also associated with cognitive decline and progression to AD in the
elderly (Carbone et al., 2014). Finally, several studies have shown
the viral load of different herpesvirus to be associated with cogni-
tive impairment in elderly individuals with vascular risk (Katan
et al., 2013; Strandberg et al., 2003, 2005), and a recent study
showed that accumulated infections, including those of HSV-1 and
CMV, might be associated with AD (Bu et al., 2014). It has been
widely demonstrated that inﬂammation is strongly associated with
neurodegeneration and cognitive impairment (Schott and Revesz,
2013). It may be that successive cycles of latency-reactivation of
these viruses trigger systemic immune responses and induce in-
ﬂammatory processes that may subsequently produce cognitive
decline. Moreover, when these viruses reach the brain, they may
also induce neuroinﬂammation, which would contribute to
neuronal death. In addition, during chronic exposure to HSV-1 and/
or HSV-2 infection, virally-induced Ab and hyperphosphorylated
tau might accumulate and persist in brain tissue, triggering a
cascade of events leading to neurodegeneration. Consistent with
this hypothesis, asymptomatic reactivation episodes promoting
neuroinﬂammation and neurodegenerative markers have been re-
ported in a mouse model of latent infection of HSV-1 (Martin et al.,
2014). Finally, HSV-2 infection might potentiate the brain damage
caused by HSV-1 or another pathogenic agent, perhaps by
enhancing reactivation in the brain. However, the mechanisms
responsible for the association between herpesvirus infections and
AD remain unclear.
In summary, the present observations show that infection
with HSV-2, like HSV-1, induces the main AD-like neuro-
degeneration markers in human neuroblastoma cells, including tau
hyperphosphorylation, anomalies in APP proteolytic processing
H. Kristen et al. / Neurobiology of Aging 36 (2015) 2737e2747 2745leading to intracellular Ab accumulation, and impairment of auto-
phagy. These ﬁndings strongly support the idea that herpesviruses
are involved in the pathogenesis of sporadic AD.Disclosure statement
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